18-158 - Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)
Status: openA Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Treatment for Ovarian Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer. IRB Number 18-158
Providers Associated With This Trial
Principle Investigator
![New pic of dr scalici]()
View ProfileJennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Professor of Interdisciplinary Clinical Oncology
